- A new study indicates that the Alzheimer’s drug lecanemab can delay the progression of the disease by up to four years.
- Patients in the earliest stages of Alzheimer's who received lecanemab showed improvement or no decline in cognitive function over a four-year trial period.
- The drug demonstrated particular promise for individuals with low levels of tau protein, with 69 per cent of this subgroup showing no decline and 56 per cent improving cognitively.
- Lecanemab, a disease-modifying drug targeting amyloid protein, was approved for use in the UK last year due to its effectiveness in slowing disease progression.
- Despite its approval, lecanemab, along with similar drugs like donanemab, was rejected for NHS use in the UK, as the benefits were deemed too small to justify the cost.
IN FULL
